Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Faldaprevir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 1.00 |
| ▸ | PPP3CB | P16298 | 1/20 | 1.00 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.55 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Faldaprevir SCHEMBL19246297 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL15462595 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL25524320 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL13556415 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL222429 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL24058604 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL227410 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| Faldaprevir SCHEMBL31554839 | 1.00 | CTSB (1.00) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL7736946 | 0.96 | CTSB (0.93) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL11947501 | 0.96 | CTSB (0.93) | CTSBPPP3CBABCC1ABCC2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732076-B2 | Solid oral dosage formulation of HCV inhibitor in the amorphous state | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| WO-2017062840-A1 | COMBINATION THERAPY FOR THE TREATMENT OF HEPATITIS C VIRUS | TREK THERAPEUTICS, PBC (US) | 2017-04-13 | — | — | WO | disclosed |
| US-20160206678-A1 | HCV COMBINATION THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2016-07-21 | — | — | US | disclosed |
| US-20160185767-A1 | SOLID ORAL DOSAGE FORMULATION OF HCV INHIBITOR IN THE AMORPHOUS STATE | TELANG CHITRA (US) | 2016-06-30 | — | — | US | disclosed |
| US-20150164884-A1 | HCV COMBINATION THERAPY | BOEHRINGER INGELHEIM INT (DE) | 2015-06-18 | — | — | US | disclosed |
| US-20150038532-A1 | Pharmaceutical Composition Of A Potent HCV Inhibitor For Oral Administration | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-05 | — | — | US | disclosed |
| US-8822496-B2 | Dosage regimens for HCV combination therapy | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-8399484-B2 | Combination therapy for treating HCV infection | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8399484-B2 | Combination therapy for treating HCV infection | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-19 | — | — | US | disclosed |
| US-20130029904-A1 | HCV COMBINATION THERAPY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-8362035-B2 | Crystalline forms of a potent HCV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-29 | — | — | US | disclosed |
| US-20120270775-A1 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-8232293-B2 | Crystalline forms of a potent HCV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232293-B2 | Crystalline forms of a potent HCV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-20120135949-A1 | COMBINATION THERAPY FOR TREATING HCV INFECTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20100093792-A1 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100093792-A1 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20100068182-A1 | COMBINATION THERAPY FOR TREATING HCV INFECTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038532-A1 | Pharmaceutical Composition Of A Potent HCV Inhibitor For Oral Administration | HAVCR2, LIPC, SLC10A1 | CTSB 497/4885PPP3CB 81/4885ABCC1 569/4885 |
| US-20100093792-A1 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR | HAVCR2, SLC10A1, ZC3HAV1 | CTSB 214/4885PPP3CB 29/4885ABCC1 646/4885 |
| US-20120270775-A1 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR | HAVCR2, SLC10A1, ZC3HAV1 | CTSB 214/4885PPP3CB 29/4885ABCC1 646/4885 |
| US-20100068182-A1 | COMBINATION THERAPY FOR TREATING HCV INFECTION | IFNAR1, SERPINB1, EIF2AK2 | CTSB 50/4885PPP3CB 83/4885ABCC1 520/4885 |
| US-20150164884-A1 | HCV COMBINATION THERAPY | HAVCR2, ZC3HAV1, SLC10A1 | CTSB 111/4885PPP3CB 62/4885ABCC1 95/4885 |
| US-20160185767-A1 | SOLID ORAL DOSAGE FORMULATION OF HCV INHIBITOR IN THE AMORPHOUS STATE | PRSS1, SPINT2, CTRL | CTSB 208/4885PPP3CB 193/4885ABCC1 350/4885 |
| US-20160206678-A1 | HCV COMBINATION THERAPY | HAVCR2, ZC3HAV1, SLC10A1 | CTSB 111/4885PPP3CB 62/4885ABCC1 95/4885 |
| US-20120135949-A1 | COMBINATION THERAPY FOR TREATING HCV INFECTION | HAVCR2, EIF2AK2, SLC10A1 | CTSB 337/4885PPP3CB 110/4885ABCC1 258/4885 |
| US-20130029904-A1 | HCV COMBINATION THERAPY | HAVCR2, ZC3HAV1, SLC10A1 | CTSB 155/4885PPP3CB 66/4885ABCC1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.